Sachetta’s CRISPR Therapeutics CRSP Stock Holding History

Sachetta’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$5.73K	Hold	105	–	–	﹤0.01%	612
2026 Q1	$5K	Sell	105 -200	-66%	-$10.5K	﹤0.01%	660
2025 Q4	$16K	Hold	305	–	–	0.01%	315
2025 Q3	$19.8K	Sell	305 -186	-38%	-$10.7K	0.01%	364
2025 Q2	$23.9K	Sell	491 -296	-38%	-$11.5K	0.01%	331
2025 Q1	$26.8K	Sell	787 -145	-16%	-$6.15K	0.01%	316
2024 Q4	$36.7K	Sell	932 -250	-21%	-$11.8K	0.01%	298
2024 Q3	$55.5K	Buy	1,182 +166	+16%	+$8.42K	0.02%	264
2024 Q2	$57.3K	Buy	1,016 +120	+13%	+$6.94K	0.02%	239
2024 Q1	$56.1K	Hold	896	–	–	0.03%	238
2023 Q4	$56.1K	Buy	+896	New	+$49.5K	0.03%	238

Other funds holding CRSP

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

WETS

Wealth Enhancement Trust Services Sioux Falls, South Dakota $792M AUM

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

BIP

Bouvel Investment Partners Phoenixville, Pennsylvania $442M AUM 70.77% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

IIM

Ipswich Investment Management Beverly, Massachusetts $474M AUM 35.58% 1-Year Est. Return

PFGIA

Patriot Financial Group Insurance Agency Westborough, Massachusetts $974M AUM 29.77% 1-Year Est. Return

BAM

Brave Asset Management Summit, New Jersey $467M AUM 33.05% 1-Year Est. Return

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

Sachetta's CRSP Position: Q2 2026 in Review

Sachetta held its CRISPR Therapeutics (CRSP) position steady in Q2 2026 at 105 shares worth $5.73K. The position accounts for ﹤0.01% of the portfolio, ranked #612.

Sachetta first reported a position in CRSP in Q4 2023 and has held it in 11 quarters since. The position peaked at $57.3K in Q2 2024. 63 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

Sachetta held 105 shares of CRISPR Therapeutics worth $5.73K as of Q2 2026.
Sachetta left its CRISPR Therapeutics share count unchanged in Q2 2026.
CRISPR Therapeutics made up ﹤0.01% of Sachetta's portfolio in Q2 2026, its #612 holding.
Sachetta first reported a position in CRISPR Therapeutics in Q4 2023 and has held it in 11 quarters since.
Sachetta's CRISPR Therapeutics position peaked at $57.3K in Q2 2024.
63 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Sachetta's 13F filing for Q2 2026, filed 15 Jul 2026.